These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 26566216)

  • 1. C-Reactive Protein Level Is an Indicator of the Aggressiveness of Advanced Pancreatic Cancer.
    Mitsunaga S; Ikeda M; Shimizu S; Ohno I; Takahashi H; Okuyama H; Ueno H; Morizane C; Kondo S; Sakamoto Y; Okusaka T; Ochiai A
    Pancreas; 2016 Jan; 45(1):110-6. PubMed ID: 26566216
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A prognostic model to predict clinical outcomes with first-line gemcitabine-based chemotherapy in advanced pancreatic cancer.
    Yi JH; Lee J; Park SH; Lee KT; Lee JK; Lee KH; Choi DW; Choi SH; Heo JS; Lim DH; Park YS; Lim HY; Kang WK; Park K; Park JO
    Oncology; 2011; 80(3-4):175-80. PubMed ID: 21701231
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic factors and prognostic index for chemonaïve and gemcitabine-refractory patients with advanced pancreatic cancer.
    Maréchal R; Demols A; Gay F; De Maertelaere V; Arvanitaki M; Hendlisz A; Van Laethem JL
    Oncology; 2007; 73(1-2):41-51. PubMed ID: 18334830
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Practical prognostic index for survival in patients with unresectable pancreatic cancer treated with gemcitabine or S-1.
    Kurihara T; Kogo M; Ishii M; Yoneyama K; Kitamura K; Shimada K; Shimizu S; Yoshida H; Kiuchi Y
    Hepatogastroenterology; 2015; 62(138):478-84. PubMed ID: 25916086
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic factors in patients with gemcitabine-refractory pancreatic cancer.
    Nakachi K; Furuse J; Ishii H; Suzuki E; Yoshino M
    Jpn J Clin Oncol; 2007 Feb; 37(2):114-20. PubMed ID: 17272317
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum levels of IL-6 and IL-1β can predict the efficacy of gemcitabine in patients with advanced pancreatic cancer.
    Mitsunaga S; Ikeda M; Shimizu S; Ohno I; Furuse J; Inagaki M; Higashi S; Kato H; Terao K; Ochiai A
    Br J Cancer; 2013 May; 108(10):2063-9. PubMed ID: 23591198
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Practical prognostic index for patients with metastatic pancreatic cancer treated with gemcitabine.
    Sawaki A; Kanemitsu Y; Mizuno N; Takahashi K; Nakamura T; Ioka T; Tanaka S; Nakaizumi A; Salem AA; Ueda R; Yamao K
    J Gastroenterol Hepatol; 2008 Aug; 23(8 Pt 1):1292-7. PubMed ID: 18700899
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment efficacy/safety and prognostic factors in patients with advanced biliary tract cancer receiving gemcitabine monotherapy: an analysis of 100 cases.
    Suzuki E; Furuse J; Ikeda M; Okusaka T; Nakachi K; Mitsunaga S; Ueno H; Morizane C; Kondo S; Shimizu S; Kojima Y; Hagihara A
    Oncology; 2010; 79(1-2):39-45. PubMed ID: 21063134
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic value of serum CA19-9 in patients with advanced pancreatic cancer receiving gemcitabine based chemotherapy.
    An X; Li YH; Lin XB; Wang FH; Feng F; Xu RH; Jiang WQ; He YJ
    Ai Zheng; 2009 Mar; 28(3):286-91. PubMed ID: 19619444
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ribonucleotide reductase M2 does not predict survival in patients with resectable pancreatic adenocarcinoma.
    Xie H; Lin J; Thomas DG; Jiang W; Liu X
    Int J Clin Exp Pathol; 2012; 5(4):347-55. PubMed ID: 22670179
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic Value of Combined Detection of Serum IL6, YKL-40, and C-reactive Protein in Patients with Unresectable Pancreatic Cancer.
    Chen IM; Johansen AZ; Dehlendorff C; Jensen BV; Bojesen SE; Pfeiffer P; Bjerregaard JK; Nielsen SE; Andersen F; Holländer NH; Yilmaz MK; Rasmussen LS; Johansen JS
    Cancer Epidemiol Biomarkers Prev; 2020 Jan; 29(1):176-184. PubMed ID: 31685562
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of metallic stents in patients with unresectable pancreatic cancer receiving gemcitabine.
    Nakai Y; Isayama H; Kawabe T; Tsujino T; Yoshida H; Sasaki T; Tada M; Arizumi T; Yagioka H; Kogure H; Togawa O; Ito Y; Matsubara S; Hirano K; Sasahira N; Omata M
    Pancreas; 2008 Nov; 37(4):405-10. PubMed ID: 18953253
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Levels of gemcitabine transport and metabolism proteins predict survival times of patients treated with gemcitabine for pancreatic adenocarcinoma.
    Maréchal R; Bachet JB; Mackey JR; Dalban C; Demetter P; Graham K; Couvelard A; Svrcek M; Bardier-Dupas A; Hammel P; Sauvanet A; Louvet C; Paye F; Rougier P; Penna C; André T; Dumontet C; Cass CE; Jordheim LP; Matera EL; Closset J; Salmon I; Devière J; Emile JF; Van Laethem JL
    Gastroenterology; 2012 Sep; 143(3):664-674.e6. PubMed ID: 22705007
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Impact of SMAD4 Loss on Outcome in Patients with Advanced Pancreatic Cancer Treated with Systemic Chemotherapy.
    Ormanns S; Haas M; Remold A; Kruger S; Holdenrieder S; Kirchner T; Heinemann V; Boeck S
    Int J Mol Sci; 2017 May; 18(5):. PubMed ID: 28534865
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-world Outcomes Among Patients Treated With Gemcitabine-based Therapy Post-FOLFIRINOX Failure in Advanced Pancreatic Cancer.
    Tsang ES; Spratlin J; Cheung WY; Kim CA; Kong S; Xu Y; Gill S
    Am J Clin Oncol; 2019 Dec; 42(12):903-908. PubMed ID: 31693510
    [TBL] [Abstract][Full Text] [Related]  

  • 16. First-line erlotinib and fixed dose-rate gemcitabine for advanced pancreatic cancer.
    Vaccaro V; Bria E; Sperduti I; Gelibter A; Moscetti L; Mansueto G; Ruggeri EM; Gamucci T; Cognetti F; Milella M
    World J Gastroenterol; 2013 Jul; 19(28):4511-9. PubMed ID: 23901226
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Do recurrent and metastatic pancreatic cancer patients have the same outcomes with gemcitabine treatment?
    Hashimoto K; Ueno H; Ikeda M; Kojima Y; Hagihara A; Kondo S; Morizane C; Okusaka T
    Oncology; 2009; 77(3-4):217-23. PubMed ID: 19729980
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Validation of C-reactive protein levels as a prognostic indicator for survival in a large cohort of pancreatic cancer patients.
    Szkandera J; Stotz M; Absenger G; Stojakovic T; Samonigg H; Kornprat P; Schaberl-Moser R; Alzoughbi W; Lackner C; Ress AL; Seggewies FS; Gerger A; Hoefler G; Pichler M
    Br J Cancer; 2014 Jan; 110(1):183-8. PubMed ID: 24201751
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nanoliposomal irinotecan plus fluorouracil and folinic acid as a second-line treatment option in patients with metastatic pancreatic ductal adenocarcinoma: a retrospective cohort study.
    Park SJ; Kim H; Shin K; Hong TH; Suh JH; Lee MA
    BMC Cancer; 2021 Nov; 21(1):1176. PubMed ID: 34732161
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic nomogram for patients with unresectable pancreatic cancer treated with gemcitabine plus nab-paclitaxel or FOLFIRINOX: A post-hoc analysis of a multicenter retrospective study in Japan (NAPOLEON study).
    Shibuki T; Mizuta T; Shimokawa M; Koga F; Ueda Y; Nakazawa J; Komori A; Otsu S; Arima S; Fukahori M; Makiyama A; Taguchi H; Honda T; Mitsugi K; Nio K; Ide Y; Ureshino N; Shirakawa T; Otsuka T
    BMC Cancer; 2022 Jan; 22(1):19. PubMed ID: 34980029
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.